[Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin].

Vereshchagin NV, Suslina ZA, Timerbaeva SL, Kashina EM, Gnezditskiĭ VV, Maksimova MIu, Rebrova OIu, Smirnova IN

Terapevticheskii arkhiv1 Jan 2001Cited by 2 (Europe PMC)

PMID11494441PepBankPUB-11494441

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In hypertensive and atherosclerotic patients, annual Cerebrolysin courses improved subjective status for at least a year.
In plain wordsIn patients with hypertension and atherosclerosis, annual Cerebrolysin courses improved subjective status for at least a year.
Peptide
Cerebrolysin
Outcome
IncreaseSubjective status
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
15 ml/day · 28 days annually for 2 yearsAs given in this study (human).
Source sentences
Summary
In mild disturbances of cognitive functions in patients with arterial hypertension and atherosclerosis courses of cerebrolysin with one-year interval produce stable improvement of subjective status, productivity of memory, attention and thinking which persist for at least a year after the course.
1 context sentence(design, population, supporting numbers)
Summary · context
Cerebrolysin was given annually (15 ml/day for 28 days) for 2 years to 42 patients in a randomized double-blind placebo-controlled study.
Report a problemFND-1149444101
02HumanRandomized controlled trialEfficacy outcome
In hypertensive and atherosclerotic patients, annual Cerebrolysin courses improved memory productivity for at least a year.
In plain wordsIn patients with hypertension and atherosclerosis, annual Cerebrolysin courses improved memory for at least a year.
Peptide
Cerebrolysin
Outcome
IncreaseMemory productivity
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
15 ml/day · 28 days annually for 2 yearsAs given in this study (human).
Source sentences
Summary
In mild disturbances of cognitive functions in patients with arterial hypertension and atherosclerosis courses of cerebrolysin with one-year interval produce stable improvement of subjective status, productivity of memory, attention and thinking which persist for at least a year after the course.
1 context sentence(design, population, supporting numbers)
Summary · context
Cerebrolysin was given annually (15 ml/day for 28 days) for 2 years to 42 patients in a randomized double-blind placebo-controlled study.
Report a problemFND-1149444102
03HumanRandomized controlled trialEfficacy outcome
In hypertensive and atherosclerotic patients, annual Cerebrolysin courses improved attention for at least a year.
In plain wordsIn patients with hypertension and atherosclerosis, annual Cerebrolysin courses improved attention for at least a year.
Peptide
Cerebrolysin
Outcome
IncreaseAttention
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
15 ml/day · 28 days annually for 2 yearsAs given in this study (human).
Source sentences
Summary
In mild disturbances of cognitive functions in patients with arterial hypertension and atherosclerosis courses of cerebrolysin with one-year interval produce stable improvement of subjective status, productivity of memory, attention and thinking which persist for at least a year after the course.
1 context sentence(design, population, supporting numbers)
Summary · context
Cerebrolysin was given annually (15 ml/day for 28 days) for 2 years to 42 patients in a randomized double-blind placebo-controlled study.
Report a problemFND-1149444103
04HumanRandomized controlled trialEfficacy outcome
In hypertensive and atherosclerotic patients, annual Cerebrolysin courses improved thinking for at least a year.
In plain wordsIn patients with hypertension and atherosclerosis, annual Cerebrolysin courses improved thinking for at least a year.
Peptide
Cerebrolysin
Outcome
IncreaseThinking
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
15 ml/day · 28 days annually for 2 yearsAs given in this study (human).
Source sentences
Summary
In mild disturbances of cognitive functions in patients with arterial hypertension and atherosclerosis courses of cerebrolysin with one-year interval produce stable improvement of subjective status, productivity of memory, attention and thinking which persist for at least a year after the course.
1 context sentence(design, population, supporting numbers)
Summary · context
Cerebrolysin was given annually (15 ml/day for 28 days) for 2 years to 42 patients in a randomized double-blind placebo-controlled study.
Report a problemFND-1149444104
05HumanRandomized controlled trialEfficacy outcome
In hypertensive and atherosclerotic patients, Cerebrolysin treatment showed a positive trend in P-300 cognitive response parameters.
In plain wordsIn patients with hypertension and atherosclerosis, Cerebrolysin treatment showed a positive trend in cognitive electrical response parameters.
Peptide
Cerebrolysin
Outcome
Direction not reportedP-300 cognitive component
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
15 ml/day · 28 days annually for 2 yearsAs given in this study (human).
Source sentences
Summary
The clinical data agree with positive trend in neurophysiological parameters of cognitive component of the response of evoked potentials P-300.
1 context sentence(design, population, supporting numbers)
Summary · context
Cerebrolysin was given annually (15 ml/day for 28 days) for 2 years to 42 patients in a randomized double-blind placebo-controlled study.
Report a problemFND-1149444105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.